No announcement yet.

Stem Cell Implant announced from Stanford University's School of Medicine

  • Filter
  • Time
  • Show
Clear All
new posts

    Stem Cell Implant announced from Stanford University's School of Medicine

    The article above was the headline here in Palo Alto this morning. Exciting news that there seems to be momentum on clinical trials.

    Thanks LizZenu,

    good news bad news kinda thing

    least now there's some thing to try that looks promising

    2010 SCINet Clinical Trial Support Squad Member

    "You kids and your cures, why back when I was injured they gave us a wheelchair and that's the way it was and we liked it!" Grumpy Old Man

    .."i used to be able to goof around so much because i knew Superman had my back. now all i've got is his example -- and that's gonna have to be enough."


      SEPT. 20, 2011

      Embryonic stem cell therapy for paralysis given to first patient in western United States

      Some excerpts:

      The Stanford University School of Medicine and Santa Clara Valley Medical Center have enrolled the fourth participant in the nation’s first trial of cells derived from human embryonic stem cells. The phase-1, FDA-approved trial is meant to test the safety of the cells in up to 10 people with recent spinal cord injuries at seven trial sites across the United States.

      The most recent patient was treated Sept. 17 at the Rehabilitation Trauma Center at SCVMC with cells prepared for injection at Stanford. Stanford neurosurgeon Gary Steinberg, MD, PhD, implanted the cells.

      The trial is being run by Geron Corp. of Menlo Park, Calif., which developed and manufactures the cells being tested. In May, Geron received a $25 million grant from the California Institute for Regenerative Medicine to continue and extend the trial to include a greater proportion of spinal cord injuries.

      Researchers at Geron collaborated with Hans Keirstead, PhD, and his laboratory team at UC-Irvine to develop a way to coax human embryonic stem cells to become a mixture of cells that include oligodendrocyte precursors. Oligodendrocytes are cells in the brain and the central nervous system that wrap nerve cells with an insulating material called myelin. This myelin sheath is necessary for the transmission of the electric signals along the spinal cord that trigger muscles to move, and relay our sense of touch and temperature. Damage to this sheath caused by trauma is a common cause of paralysis.

      During the procedure, Steinberg applied about 2 million of the special cells, called GRNOPC1, directly into the injured area of the patient’s spinal cord.

      Following the surgery at SCVMC, the patient entered an intensive inpatient rehabilitation program under the supervision of McKenna and James Crew, MD, who are specialists in spinal cord injury medicine. Researchers will now monitor the patient for any adverse events to confirm that the cells are safe for use in humans.

      In June, Geron reported preliminary results of the trial on the first two patients at two meetings: the 2011 International Conference on Spinal Cord Medicine and Rehabilitation and the 2011 Spine Symposium. The results so far show no significant adverse effects experienced by either patient. If this phase-1 trial of 10 patients shows that the treatment is safe, future trials will be designed to determine whether the cells are able to improve participants’ clinical symptoms.

      complete article: